A Novel L-Asparaginase from Enterobacter sp. Strain M55 from Maras Salterns in Peru

• Published in: Chemical and Biochemical Engineering Quarterly 2022-07, Vol.36 (2), p.167-173
• Main Authors: Hurtado, A, Flores-Santos, J.C, Flores-Fernandez, C.N, Saavedra, S, Santos, J.H.P.M, Pessoa-Junior, A, Lienqueo, M.E, Bayro, M.J, Zavaleta, A.I
• Format: Article
• Language: English
• Subjects: Amino acids; Asparaginase; clinical treatment; Enterobacter; Ethylenediaminetetraacetic acid; l-asparaginase; l-glutaminase; Physiological aspects; saline enviroments; saline environments
• ISSN: 0352-9568; 0352-9568; 1846-5153
• DOI: 10.15255/CABEQ.2022.2064

L-Asparaginase (ASNase) is used in medicine for neoplasms treatment and in food industry for mitigation of acrylamide in high-temperature processed food. In medicine, commercial ASNases have exhibited side effects and L-glutaminase (GLNase) activity affecting the clinical treatment. The aim of this work was to study a novel ASNase from Enterobacter sp. M55 isolated from Maras Salters in Peru, which was purified and biochemically characterised. This ASNase exhibited a Km of 5.71 mM and a Vmax of 0.16 [micro]mol [mL.sup.-1] [min.sup.-1], as well as an optimum temperature and pH of 37 [degrees]C and 6, respectively. Moreover, a good activity (80%) was observed at physiological pH. Likewise, the enzyme increased its activity by around 50% in presence of urea, glutathione, and glucose. Whilst in presence of serum compounds, it kept more that 60% of activity. In addition, this ASNase showed low GLNase activity. Keywords: L-asparaginase, L-glutaminase, Enterobacter, saline environments, clinical treatment